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Abstract 
Background: Stent placement for middle cerebral artery (MCA) stenosis remains a technical and clinical challenge. 
Our purpose was to assess the safety and feasibility of balloon-expandable stent (BES) for patients with symptomatic 
M1 stenosis of MCA, and to introduce our experience during the procedure.
Methods: In the study, we analyzed retrospectively 37 patients with M1 stenosis of the MCA ranged from 70 to 90 % 
in diameter reduction and refractory to medical therapy between January 2012 and January 2015. All the patients 
underwent angioplasty and stenting with BES, and followed up continuously.
Results: Thirty-five out of 37 patients were successfully followed up and available until now. The technical successful 
rate was 100 % for all the lesions. The complication rate was 0 during the procedure. Stroke occurred to one patient 
at 4th day after the procedure. There were two patients experiencing slight stroke after 8 months. Two patients were 
found re-stenosis >50 % without any symptom. The stroke rate of 12 months was 8.57 % (3/35).
Conclusions: Angioplasty associated with BES appears to be safe and feasible for the patients with symptomatic M1 
stenosis of MCA. Our experiences about the BES may be valuable for decreasing the complication. However, further 
study is needed.
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Background
In Asia, Europe and North America, stroke is the third 
cause of death and disability (Thom et al. 2006; Donnan 
et al. 2008). Compared with the whites, primary athero-
sclerotic at MCA may play a significant role in Asians 
(Caplan et al. 1986; Li and Wong 2003). In Chinese pop-
ulation, intracranial atherosclerosis is more common 
(Suri and Johnston 2009). Symptomatic MCA stenosis 
is a common cause of ischemic stroke. Therefore, much 
attention has been paid in this research area in the past 
years in China.
Nowadays, the main treatments for the intracranial 
stenosis include medical therapy, percutaneous translu-
minal angioplasty (PTA) or percutaneous transluminal 
angioplasty and stenting (PTAS), and surgical interven-
tion. But the optimal treatment remains controversial. 
There was a high rate of the stroke in the patients with 
MCA stenosis, even with the optimal medicine treat-
ment (Chimowitz et  al. 1995). So the therapeutic effect 
of expectant treatment with antiplatelet and anticoagula-
tion is limited (Chimowitz et al. 2005). PTAS have been 
considered as an alternative treatment (Jiang et al. 2004, 
2007; Kim et al. 2005; Suh et al. 2008). Stent placement 
was certified to be safe and efficient (Lee et  al. 2005; 
Mohammadian et al. 2012; Zhang et al. 2012). Nowadays, 
there are two types stents used in intracranial athero-
sclerotic stenosis, one is self-expandable stent (SES), and 
the other is balloon-expandable stent (BES). Because of 
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the flexibility of the SES, its’ usage was more widespread. 
But the SAMMPRIS trial (Chimowitz et  al. 2011) and 
the VISSIT trial (Zaidat et al. 2015) revealed the negative 
results. Recently, the safety and efficacy were certified 
again (Miao et al. 2015).
The purpose of this study was to introduce the expe-
rience of BES for the patients with symptomatic MCA 
stenosis.
Methods
Between January 2012 and January 2015, we retrospec-
tively analyzed the medical records of 37 patients under-
went PTAS using the BES (APOLLO, Micro-port Neuro 
Tech, China) for the atherosclerotic stenosis of MCA. 
The study was approved by the institutional review board, 
and the way of endovascular treatment was informed 
written consent by all the patients.
APOLLO is one type of balloon-expandable stent 
used to treat intracranial arterial stenosis, which is pro-
duced by MicroPort Scientific Corporation of China. The 
advantage of the stent is its supporting force and flexibil-
ity. The conveyor is the rapid exchange balloon catheter. 
It has excellent pushing and crossing ability.
The inclusion criteria of the study were as follows: 
recurrent transient ischemic attack (TIA) or stroke 
despite optimal medical therapy related to the symp-
tomatic atherosclerotic stenosis in the M1 segment of 
MCA; the digital subtraction angiography (DSA) show-
ing the stenosis ≥70 %; the type of lesion was Mori A or 
B (Mori et al. 1998); The age of the patients was between 
30 and 75 years.
The exclusion criteria were as follows: non-atheroscle-
rotic arterial stenosis; the patients with tumors, aneu-
rysms, heart failure, hepatosis, kidney failure, ulcer, 
hematological system diseases, vasculitis, hyperthyroid-
ism; allergic reaction for aspirin, clopidogrel and iodine; 
the lesion angulated <135 degree; patients with the 
severe neurological impairment could not take care of 
themselves in their life.
All patients were pre-medicated with doses of aspirin 
(100  mg/d) plus clopidogrel (75  mg/d) at least 5  days 
before the endovascular therapy.
The therapeutic procedures were performed during the 
second angiography. All endovascular procedures were 
performed under local anesthesia by a neuroradiologist. 
The right femoral artery was selected the percutaneous 
access. And an 8F sheath (APOLLO, Micro-port Neuro 
Tech, China) was inserted after the femoral puncture. 
Before the therapeutic procedure, the patients received 
systemic heparinization by a bolus injection of heparin 
75 IU/kg. Then a 6F guiding catheter (APOLLO, Micro-
port Neuro Tech, China) was inserted into the distal 
C2 of internal cerebral artery. Then a micro wire went 
straight through the guiding catheter to fix to the M2 of 
the MCA. If the access was tortuous and the stent could 
not get to the right position, the second micro wire was 
used to increase the support force. Under the road-map 
image, the stent passed through the stenosis carefully 
along the micro wire (If using the second micro wire, 
it should be pulled out at the time). Then use the “step-
by-step” multi-step pressure technique to deploy the 
stent. The stent was delivered from the wire by dilating 
the balloon by 3 atm for 3 s firstly, then the pressure was 
increased to 4 atm for 3 s, 5 atm for 3 s to reduce the resi-
due stenosis gradually. The maximum pressure was no 
more than 6 atm to avoid rupture.
All patients took orally clopidogrel (75 mg/d) for 1 year. 
Aspirin was used continuously (100  mg/d). Low-molec-
ular-weight heparin calcium injection was used by sub-
cutaneous injection every 12  h for at least 3  days. All 
patients were followed up continuously. Data analysis was 
performed by using Sigmaplot 10.0 statistical software.
Results
We studied 37 patients (21 men and 16 women) rang-
ing in age from 32 to 72 years (mean age 55.1 years). All 
patients experienced TIA (n = 6) or stroke (n = 31). All 
the stenosis of the M1 segment of MCA was directly 
responsible for the symptoms.
The technical successful rate was 100  %. For tortu-
ous vessel, we used the double-micro-wire technique to 
increase the rate of the technique success (Fig. 1). Mean 
preprocedual stenosis was 80.27 % (range 70–90 %). Post-
procedure the residual stenosis was 0–20  % (the mean 
of 7.30 ± 5.60 %). During the procedure, there was none 
complication, including thrombosis in stent, artery rup-
ture, lenticulostriate artery occlusion.
Of the 37 patients who underwent PTAS, followed-up 
successfully were 35 people. Clinical follow-up was avail-
able up to now. 30-days stroke rate was 2.70  % (1/37). 
One patient occurred stroke at 4  days after the proce-
dure. DSA certified acute thrombosis in the stent. We 
accessed the vascular successfully (Fig.  2). Micro-wire 
passed through the occlusion. Then we processed PTA. 
But there was more thrombus, then we used GPIIb/IIIa 
receptor antagonist (Tirofiban Hydrochlorid). There were 
two patients occurring slight stroke after 8 months. The 
one occurred re-stenosis >50  % (Fig.  3). The thrombus 
completely blocked in the stent in the other one (Fig. 4). 
But the neurological deficit symptom was disappeared 
completely by medical therapy. The rest did not show 
any stroke or TIA. The 12 months stroke rate was 8.57 % 
(3/35). However, two patients were found re-stenosis 
>50 % without any symptom (Fig. 5). Clinical follow-up 
for the patients with the longest time was 36  months. 
DSA showed a perfect result (Fig. 6).
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Discussion
The controversy about the treatment of the endovascular 
stenting for patients with symptomatic intracranial arte-
rial stenosis is going on. Complication is one of the rea-
sons. We used BES for the patients with MCA stenosis, 
and obtained satisfactory results. Using the multi-step 
technique could decrease the complication.
Gomez used the stent to treat the stenosis of MCA 
(Gomez et  al. 2000). Soon after, the coronary BES was 
used to treat the MCA stenosis (Shin et  al. 2003; Kim 
et al. 2004). Also, it was certified to be effective and fea-
sible (The SSYLVIA Study Investigators 2004; Jiang et al. 
2004, 2007; Fiorella et  al. 2007). Especially the appear-
ance of the Winspan stent (Henkes et al. 2005), the treat-
ments of the symptomatic intracranial arterial stenosis are 
showing a new situation. However, the SAMMPRIS trial 
certified aggressive medical management was superior to 
PTAS (Chimowitz et  al. 2011). The VISSIT trial did not 
Fig. 1 A 45-year-old man with a stroke. a DSA shows severe stenosis (about 90 %) in the M1 portion of the left MCA and tortuous pathway, b the 
double-micro-wire was fixed, c the stent is reaching to the right position and expanded gradually, d DSA shows recanalization of the diseased seg-
ment after the post-procedure
Fig. 2 A 51-year-old man with a stroke. a DSA shows severe stenosis (about 80 %) in the M1 portion of the right MCA, b DSA shows recanalization 
of the diseased segment after the post-procedure, c DSA shows an acute thrombosis in the stent at 4-day after the procedure, d vascular recanaliza-
tion using the micro-wire
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support the use of BES (Zaidat et al. 2015). Nevertheless, 
Miao revealed the safety and efficacy of endovascular 
stenting (Miao et al. 2015). The reporters found that there 
was no significant difference between the SES and the BES 
about the follow-up clinical outcomes (Yue et al. 2011b). 
But the expense and the complicated procedure of the 
SES restricted the use of the Winspan stent (Zaidat et al. 
2008), especially in developing countries. For this reason, 
we use the BES to treat the MCA stenosis.
The most severe complication was intracranial hemor-
rhage (Brus-Ramer et al. 2010). The rate was 7.5 % (Jiang 
et  al. 2004). In addition, the perforating artery occlu-
sion may cause severe cerebral infarction. Jiang found 
that the rate of perforating vessel occlusion near the 
site of stenosis of was 3.0  % (Jiang et  al. 2006). In par-
ticular, perioperative complication rate was 10–20  % in 
the patients with BES (Chow et  al. 2005). We used the 
APOLLO stent to treat the MCA stenosis. The success-
ful rate of stent-angioplasty was 100 % in this study. No 
infarction or hemorrhage was observed during the pro-
cedure. During the procedure, we used the way of step-
by-step to deploy the stent. The results indicated that the 
way was safe and effective. Firstly, it reduced the rate of 
the rupture of artery. During the first step, the stent gave 
the weak muscle fibers of the artery a buffer chance. Sec-
ondly, it made the atherosclerotic plaque “find” the posi-
tion of them. So it avoided blocking the lenticulostriate 
artery. This was a hypothesis. The specific principle needs 
Fig. 3 A 42-year-old woman with a stroke. a DSA shows severe stenosis (about 80 %) in the M1 portion of the right MCA, b DSA shows excellent 
recanalization of the diseased segment after the BES positioned at the lesion, c 8 months later, DSA shows that the degree of re-stenosis is more 
than 70 %. d the second BES is positioned to improve the lesion of the restenosis
Fig. 4 A 51-year-old man with a stroke. a DSA shows severe stenosis (about 90 %) in the M1 portion of the left MCA, b the BES is positioned at the 
lesion, and the micro wire is anchored in the distal branch of the MCA, then the balloon is expanded gradually, c DSA shows excellent recanalization 
of the diseased segment immediate post-procedural, d at the 8 months, the thrombus blocked the artery in the stent completely. But the vascular 
compensatory through pial artery was complete
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future study. Certainly, if there are obvious and more the 
lenticulostriate arteries nearby the lesion, it should be 
cautious to choose BES. The procedural complication is 
associated with the lesion with calcification or without. 
We did not confirm the lesion calcification or without, 
because there is no High Resolution Magnetic Resonance 
Imaging.
Vessel tortuosity may increase the technical difficulty 
thus raising the risks. Some investigators reported that 
the stent could not arrive at the right position due to the 
tortuous artery pathway (Kim et al. 2004). This was one 
of the major reasons of failure. In this condition, we used 
double-micro-wire to increase the support power. This 
way not only reduced the single micro wire inactivity 
bumped the tunica intimae, but also shortened the whole 
time of the procedure. This is another cause of the high 
success rate. For the longer lesion (Mori C) and exces-
sively tortuous pathway, BES is not a better choice. After 
all, the BES is less flexible than SES.
Because the residual stenosis rate was one of the major 
factors affecting the restenosis (Yue et al. 2011a), so less 
residual stenosis is more beneficial. In the SES, the resid-
ual stenosis rate was over 10 % (Kim et al. 2012; Zhang 
et al. 2012) because of the balloon dilatation angioplasty 
Fig. 5 A 58-year-old woman with a stroke. a DSA shows severe stenosis (about 80 %) in the M1 portion of the right MCA, b the BES is positioned at 
the lesion, then the balloon is expanded gradually, c DSA shows excellent recanalization of the diseased segment immediate post-procedural,  
d 12 months later, DSA shows that the degree of re-stenosis is more than 50 %
Fig. 6 A 55-year-old woman with a stroke. a DSA shows severe stenosis (about 90 %) in the M1 portion of the right MCA, b The BES is positioned at 
the lesion, c DSA shows excellent recanalization of the diseased segment immediate post-procedural, d 36 months later, DSA shows a perfect result
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without simultaneous stenting. The problem was resolved 
by the BES. BES may have a lower degree of residual ste-
nosis than SES (Miao et  al. 2015). We obtained an out-
standing angiographic result with BES. In some cases, the 
residual stenosis was 0.
The SSYLVIA study reported the restenosis rate of 
≥50 % at 6 months was 32.4 % (The SSYLVIA Study Inves-
tigators 2004). However, the investigators reported that 
there was no restenosis in the cases with drug-eluting 
stent (Lee et al. 2013). The restenosis is associated with the 
angle of the lesion. When the lesion was tortuous, the type 
of Mori C, the rate of stroke was 87 %, the rate of reste-
nosis was 100 % (Mori et al. 1998). In this study, we had 
chosen the lesion angled >135 degree to decrease the rate 
of the restenosis. Two patients showed stroke at 8-month. 
One had restenosis over 50  %. The reason was that she 
did not take orally aspirin and clopidogrel regularly. We 
used another stent to treat the restenosis. Up to now, 
she showed none ischemic symptom. In the other case, 
the thrombus blocked the artery in the stent completely. 
There was not any other reason except for unhealthy life-
style. But the vascular compensatory through pial artery 
was more complete, so the patient showed slight neuro-
logical impairment. Through drug treatment, he had none 
sequela. The stent provided collateral circulation buffering 
time. So even under the circumstances of the thrombosis 
in the stent, the collateral circulation could ensure ade-
quate blood supply to the corresponding functional areas.
Conclusions
In this study, BES appeared to be safe, effective and feasi-
ble for MCA stenosis. The whole procedure was simple. 
It may be suitable for Chinese and the patients of other 
developing countries. This is our experience of the BES. 
However, the number of the patients included was rela-
tively small. Further study should be prompted on a large 
scale, multi-center research.
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